Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Sponsor
M.D. Anderson Cancer Center
Status
Completed
NCT ID
NCT03063619
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Intervention
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Condition
Mammographically Dense Breast
Investigators
Banu Arun, MD